Psoriatic Arthritis (PsA) Treatment Market Size, Trends, Share, Growth, and Opportunity Forecast, 2025 – 2032 Global Industry Analysis By Type (Biologics [TNF‑α Inhibitors, IL‑17 Inhibitors, IL‑23 Inhibitors], Targeted Synthetic DMARDs [JAK Inhibitors, TYK2 Inhibitors], Conventional DMARDs, NSAIDs, and Biosimilars), By Application (Peripheral Arthritis, Nail Psoriasis, Axial Disease, Enthesitis, and Dactylitis), By End-User (Hospitals, Specialty Clinics, and Homecare & Self‑administration), and By Geography (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

By Type

·         Biologics (TNF‑α Inhibitors, IL‑17 Inhibitors, IL‑23 Inhibitors)
·         Targeted Synthetic DMARDs (JAK Inhibitors, TYK2 Inhibitors)
·         Conventional DMARDs
·         NSAIDs
·         Biosimilars

By Application

·         Peripheral Arthritis
·         Nail Psoriasis
·         Axial Disease
·         Enthesitis
·         Dactylitis

By End-User

·         Hospitals
·         Specialty Clinics
·         Homecare & Self‑administration

Companies Profiled

·         AbbVie Inc.
·         Johnson & Johnson
·         Amgen Inc.
·         Novartis AG
·         Eli Lilly and Company
·         Pfizer Inc.
·         UCB S.A.
·         Bristol-Myers Squibb Company
·         Sun Pharmaceutical Industries Ltd.
·         Biogen Inc.